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Table 1. Comparison of calcium-mimetic AMG 073 at 50 and 100 mg/day
Lindberg (KI 2003;63:248) Quarles (JASN 2003;14:575)
AMG 50 mg Placebo AMG 100 mg Placebo
Patients Nb:total No. at maximum maintenance dose 34 (21) 34 31 (17) 31
Ca-PO4 binder Ca element mg/day No change No change −2 +294
Sevelamer mg/day None None −111 +163
Calcitriol/paricalcitol dose change lg/wk None None −0.9/−6.5 −1.3/−7
Introduction of calcitrol or paricalcitol No. patients – – 10/4 3/4
Changes at maintenance period versus baseline %
SCa −4.7b 0 −4.6b +2.6
SPO4 −7.5b +11 −2.6 NS +7
SCa × SPO4 −12b +11 −7.9a +11
PTH −26b +22 −32b −3
PTH absolute value baseline/maintenance 637/460 632/701 626/451 583/552




100 mg/day [2], surprisingly, shows no obvious better re-
sults in parathyroid hormone (PTH) suppression (−26 vs.
−32%) or in Ca × PO4 product control (−12 vs. −7.9%).
Although the two calcium mimetic–treated groups were
not randomized, they had comparable baseline charac-
teristics regarding serum concentration of PTH, Ca and
PO4, and use of vitamin D and phosphate binder. Regard-
ing concomittant therapy change differences between
active and placebo-treated groups, stability in both PO4
binder and vitamin D was documented only in the 50 mg
study. Indeed, in the 100 mg study, although weekly doses
of calcitriol and paracalcitol were the same in both groups,
the vitamin D treatment had to be started in 14 patients
receiving AMG 073 versus only 7 in patients receiving
placebo. This higher incidence of new vitamin D treate-
ment in the 100 mg titrated group explains that, in spite of
this twice higher dose, the decrease of serum calcium was
comparable in both studies (−4.6 and −4.7%), whereas
the decrease of serum phosphate was more than twice
smaller (−2.6 vs. −7%) and not significantly different
from the control group as it was in the 50 mg study
(Table 1). Indeed, calcitriol is known to increase active
intestinal absorption of both calcium and phosphate on
an equimolar basis [3].
We suggest, therefore, that correcting the hypocal-
cemic effect of the calcimimetic by increasing calcium-
phosphate binder rather than introducing calcitriol would
be more efficient to decrease serum phosphate for the
same decrease in PTH as shown by a randomized
study [4].
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Vitamin C improves vascular
resistance in patients with
chronic renal failure
To the Editor: Vitamin C, an antioxidant, has been
widely used as a free radical scavenger. In a recent is-
sue of Kidney International, the article by Cross et al [1]
concluded that acute parental administration of ascor-
bic acid reduced oxidant stress and improved nitric oxide
(NO)-mediated resistance vessel dilatation in uremic pa-
tients. However, they also revealed significantly increased
lipid hydroperoxides. Ascorbic acid could exert its pro-
oxidant effect through Fenton chemistry to generate free
radicals [2]. In our recent study, the increased generation
of superoxide detected by leucigenin-enhanced chemilu-
minescence was noted following bolus administration of
ascorbic acid 300 mg at the end of the hemodialysis (HD)
session (Fig. 1). The pro-oxidant effect of bolus injection
of ascorbic acid is especially evident in iron-overloaded
uremic patients [3]. Currently, many dialysis patients are
treated with intravenous iron and may have received
multiple blood transfusions. Consequently, some may be-
come iron overloaded. Without monitoring iron indices,
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Fig. 1. The changes of leucigenin-enhanced chemiluminescence
(LucCL) intensity were more significantly increased in the ascorbic
acid–treated group than in the control group of hemodialysis patients.
(1261.0 ± 401.9 vs. 77.4 ± 62.5, ∗P < 0.05).
acute administration of ascorbic acid in larger doses may
have potential hazards in generating larger amount of
free radicals.
The study has demonstrated that NO involves the dila-
tor mechanism of acetylcholine, while ascorbic acid still
has an insignificant dilator effect in the presence of L-
NMMA (compared with L-NMMA alone). Whether the
action of vitamin C promotes the bioactivity of endoge-
nous NO is not known here. Furthermore, acidification
was known to augment NO-mediated relaxation in rat
artery [4]. Large dose infusion of ascorbic acid, with low
pKa of 4.2, might overload the buffer system in the local
uremic vascular milieu. This dilator effect may act possi-
bly through the acidosis of the biologic system.
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Proteinuria dipstick test: Is it
time to change?
To the Editor: In their recent paper published in
Kidney International, Iseki et al [1] demonstrated that
proteinuria, assessed by dipstick urinalysis, is an inde-
pendent risk factor of end-stage renal disease (ESRD) in
a mass screening setting.
Sensitivity of dipstick for proteinuria is low (albumin
>250 mg/L), and the cost for each strip is United States
dollars $0.71. The correct evaluation of proteinuria re-
quires a timed urine collection or, alternatively, the use of
the protein:creatinine ratio (P/C) on spot-morning urine
[2, 3]; the cost of reagents for P/C is United States dollars
$0.34.
We compared the data obtained from the analysis of
24-hour proteinuria, of the P/C, and of the dipstick test
in 297 patients with different kidney diseases, proteinuric
or not. We found a good correlation between the values
of 24-hour proteinuria and P/C (R = 0.82), and a lower
correlation between 24-hour proteinuria and dipstick test
(R = 0.75), and between P/C and dipstick test (R = 0.72).
In 54 patients (18.2%) the dipstick resulted negative; by
contrast, both of the other methods showed a pathologic
proteinuria.
In our experience the P/C is a reliable estimation of the
24-hour proteinuria, more sensitive than dipstick.
We conclude that P/C is a feasible, sensitive, low in cost,
simple test. Actually, in industrialized countries, this test
should be considered for a mass health screening in order
to detect early signs of ESRD and to allow appropriate
renoprotective treatments [4].
Furthermore, the P/C should be performed routinely
in selected settings for detecting low increases of protein-
uria otherwise not revealed by dipstick test.
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